The adoption of continuous glucose monitoring (CGM) is growing among both type 1 and type 2 diabetes populations, but its clinical use remains low. A key challenge is the lack of clear glycemic targets, which the Advanced Technologies & Treatments for Diabetes (ATTD) Congress panel addressed by recommending standardized CGM metrics like time in range, time below range, and time above range. The panel also emphasized the importance of personalized therapy and a collaborative approach between healthcare providers and patients to optimize CGM use in clinical practice.

The ATTD consensus further notes the limitations of A1C as a sole diabetes marker, as it misses acute glycemic excursions and variability. When paired with CGM data, a more comprehensive glucose profile can be achieved. The panel proposed CGM-based targets for different populations, including adjustments for pregnant and high-risk individuals. Key metrics like TIR are linked to improved clinical outcomes, such as reduced diabetic retinopathy and microalbuminuria, and offer significant benefits when tailored to each patient’s needs.

Reference: Battelino T, Danne T, Bergenstal RM, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care. 2019;42(8):1593-1603. doi: 10.2337/dci19-0028.